EYS mutations and implementation of minigene assay for variant classification in EYS-associated retinitis pigmentosa in northern Sweden

Ida Maria Westin1, Frida Jonsson1, Lennart Österman1, Monica Holmberg1, Marie Burstedt2 & Irina Golovleva1*

Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of inherited retinal degenerations. The ortholog of Drosophila eyes shut/spacemaker, EYS on chromosome 6q12 is a major genetic cause of recessive RP worldwide, with prevalence of 5 to 30%. In this study, by using targeted NGS, MLPA and Sanger sequencing we uncovered the EYS gene as one of the most common genetic cause of autosomal recessive RP in northern Sweden accounting for at least 16%. The most frequent pathogenic variant was c.8648_8655del that in some patients was identified in cis with c.1155T>A, indicating Finnish ancestry. We also showed that two novel EYS variants, c.2992_2992+6delinsTG and c.3877+1G>A caused exon skipping in human embryonic kidney cells, HEK293T and in retinal pigment epithelium cells, ARPE-19 demonstrating that in vitro minigene assay is a straightforward tool for the analysis of intronic variants. We conclude, that whenever it is possible, functional testing is of great value for classification of intronic EYS variants and the following molecular testing of family members, their genetic counselling, and inclusion of RP patients to future treatment studies.

1Medical Biosciences/Medical and Clinical Genetics, University of Umeå, 901 87 Umeå, Sweden. 2Clinical Science/Ophthalmology, University of Umeå, 901 85 Umeå, Sweden. *email: irina.golovleva@umu.se
Table 1.  EYS variants in arRP patients in the northern part of Sweden. aTwo variants are present on one allele and another variant is present on the second allele in this patient. bPathogenic variants were present on both alleles in this patient. cDissociation breakpoints remain unknown. dOnly one likely pathogenic variant was found. All sequence positions are denoted according to NM_001142800.1 (human reference genome GRCh38/hg38).

| Family | Sample | Age  | Origin  | Allele 1          | Allele 2          | Zygosity | Protein change |
|--------|--------|------|---------|--------------------|-------------------|----------|----------------|
| 012    | RP15   | 92 y.o | Västerbotten | c.[1155T>A;8648_8655del] | c.2992_2992+6delinsTG | hetero   | p.[(Cys385*, Thr2883Lysfs*4)];[(Phe950 Thrfs*4)] |
| 012    | VC101  | 87 y.o | Västerbotten | c.[1155T>A;8648_8655del] | c.1155T>A;8648_8655del | homo     | p.[(Cys385*, Thr2883Lysfs*4)];[(Cys385*, Thr2883Lysfs*4)] |
| 335    | RP103  | 85 y.o | Västernorrland | c.[1155T>A;8648_8655del] | c.3877+1G>A | hetero   | p.[(Cys385*, Thr2883Lysfs*4)];[(Thr1229 Lysfs*24)] |
| 335    | RP105  | 90 y.o | Västernorrland | c.[1155T>A;8648_8655del] | c.3877+1G>A | hetero   | p.[(Cys385*, Thr2883Lysfs*4)];[(Thr1229 Lysfs*24)] |
| 501    | RP6795 | 17 y.o | Norrbotten   | c.8648_8655del | g.(63721660_63723982)_(63728011_63734700)dup | hetero   | p.[(Thr2883Lysfs*4)];[(Thr1229 Valfs*24)] |
| 501    | RP5436 | 19 y.o | Norrbotten   | c.8648_8655del | g.(63721660_63723982)_(63728011_63734700)dup | hetero   | p.[(Thr2883Lysfs*4)];[(Thr1229 Valfs*24)] |
| 501    | RP6019 | 57 y.o | Norrbotten   | c.8648_8655del | g.(63721660_63723982)_(63728011_63734700)dup | hetero   | p.[(Thr2883Lysfs*4)];[(Thr1229 Valfs*24)] |
| simplex| RP26   | 65 y.o | Norrbotten   | c.8648_8655del | c.8648_8655del | homo     | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
| simplex| RP95   | 62 y.o | Norrbotten   | c.6284C>T | ? | hetero   | p.[(Pro2095Leu)];[(Thr2883Lysfs*4)] |
| simplex| RD154  | 49 y.o | Västerbotten | c.8648_8655del | c.8648_8655del | homo     | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
| simplex| RP165  | 59 y.o | Västerbotten | c.8648_8655del | c.8648_8655del | homo     | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
| simplex| RP6019 | 57 y.o | Norrbotten   | c.8648_8655del | c.8648_8655del | homo     | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
| simplex| RP18   | 81 y.o | Norrbotten   | c.8648_8655del | ? | hetero   | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
| simplex| RP74   | 77 y.o | Norrbotten   | c.8648_8655del | ? | hetero   | p.[(Thr2883Lysfs*4)];[(Thr2883Lysfs*4)] |
Characterization of EYS variants identified in arRP cohort from northern Sweden. All sequence positions are denoted according to NM_001142800.1 (GRCh38/hg38 human reference genome). dbSNP –database of single nucleotide variations at https://www.ncbi.nlm.nih.gov/snp/. gnomAD-genome aggregation database at https://gnomad.broadinstitute.org/. DANN/CADD-prediction tools for annotating of pathogenicity (Quang et al. 2015; Rentzsch et al. 2019) MutationTaster predicts a disease-causing potential of single nucleotide polymorphism (Schwarz et al. 2014). GERP-Genomic Evolutionary Rate Profiling (GERP) is a conservation score across alignments of the genomes of 35 mammals (Cooper et al. 2005). FATHMM-MKL represents normalized functional predictions from numerous non-synonymous computational predictions algorithms (Shihab et al. 2017). ACMG- standards and guidelines for the interpretation of sequence variants recommended by the American College of Medical Genetics and Genomics (Richards et al. 2015).

In silico prediction of the c.2992_2992+6delinsTG and c.3877+1G>A variants on splicing. To evaluate association of the two EYS intronic variants with arRP and their role in gene splicing, we first performed in silico analysis. The effect of splice-site variants was calculated by the algorithms included in Alamut Visual software version 2. Both variants were classified as pathogenic according to ACMG. The c.2992_2992+6delinsTG variant in intron 19 of the EYS gene was predicted to alter the donor site at a risk of 100% by MaxEnt, 100% by NNSPLICE and 100% by HSF, giving an average risk prediction of aberrant splicing of 100%. The canonical c.3877+1G>A variant in intron 25 of the EYS gene was also predicted to alter the donor site 1 bp upstream of the mutation at a risk of 100% by MaxEnt, 100% risk by NNSplice and 100% risk by HSF, giving an average risk prediction of aberrant splicing of 100%.

In vitro splice assay using EYS minigenes carrying c.2992_2992+6delinsTG variant. To analyse how the EYS c.2992_2992+6delinsTG variant affects splicing, wt and mt EYS minigenes covering exon 19 and part of the adjacent intron sequence were generated (Fig. 1). The minigenes were transfected into HEK293T and ARPE-19 cells and the splicing was analysed. The EYS minigene transected into HEK293T cells resulted in one distinct product of 406 bp (Fig. 1). By sequencing, we could confirm that the 406 bp product represents correct splicing of exon 19. Transfection of the mt EYS c.2992_2992+6delinsTG minigene into HEK293T cells resulted in a 260 bp product, due to exon 19 skipping (Fig. 1). Transfection of the ARPE-19 cells with wt EYS minigene resulted in three products; 406 bps, ~ 320 bps and 260 bps (Fig. 1), where correctly spliced transcript resulted in a 260 bp product, due to exon 19 skipping (Fig. 1). Thus, we observed exon skipping in both human embryonic kidney HEK293T and retinal pigment epithelium ARPE-19 cells when the c.2992_2992+6delinsTG minigene was transfected into ARPE-19 only the product with skipped exon 19 was observed (Fig. 1). Thus, we observed exon skipping in both human embryonic kidney HEK293T and retinal pigment epithelium ARPE-19 cells when the c.2992_2992+6delinsTG variant was introduced. Skipping of exon 19 is predicted to result in a premature stop codon and due to absence of exon 19, the amino acid nomenclature would be p.(Phe950Hisfs*4).

In vitro splice assay using EYS minigenes with the c.3877+1G>A variant. To demonstrate how the EYS c.3877+1G>A variant affects splicing, wt and mt EYS minigenes were generated (Fig. 2). The minigenes were transfected into HEK293T and ARPE-19 cells and the splicing outcome was analysed. The wt EYS minigene transfected into HEK293T cells resulted in two distinct products of 572 bp and 453 bp respectively (Fig. 2). The 453 bp product corresponded to correct splicing of exon 25, while the 572 bp fragment was the result of using exon 25 donor site and pSPL3 alternative donor site. The sequencing revealed inclusion of 119 nucleotides that covered EYS intron 25 sequence from c.3877+253 to c.3877+266 (14 bp) plus the entire NotI restriction site (8 bp), and continuing 97 bp into the pSPL3 vector before splicing out at a cryptic donor site within the pSPL3, and thereafter joining pSPL3 acceptor site SAV.

Transfection of the mt EYS c.3877+1G>A minigene into HEK293T resulted in three products: 582 bp, 463 bp and 260 bp (Fig. 2). The 582 bp fragment had additional 10 bp of intron 25 sequence (c.3877+10) and 119 nucleotides as seen in the wt construct. The 463 bp product was shown to include the same 10 bp of intron 25
sequence as seen in the 582 bp product. No correctly spliced product was observed with the mt EYS\textsuperscript{c.3877+1G>A} minigene. The 260 bp fragment was the result of exon 25 skipping. Transfection of the ARPE-19 cells with wt EYS minigene resulted in two products: 453 bps and 260 bps (Fig. 2), with the majority representing the correctly spliced transcript. When the mt EYS\textsuperscript{c.3877+1G>A} minigene was transfected into ARPE-19 only the product with exon 25 skipping was observed (Fig. 2). Thus, exon skipping was demonstrated in both human embryonic kidney HEK293T and retinal pigment epithelium ARPE-19 cells when the c.3877+1A variant was introduced. Skipping of exon 25 would result in an early stop codon and due to absence of exon 25, the amino acid nomenclature would be p.(Thr1229Valfs*21).

**Clinical findings.** In this study we could only investigate clinical presentation of EYS-associated RP in three individuals from Family 501 (Table 3). Visual acuity was unaffected with no significant cataract or other ophthalmologic diseases present during the first two decades for all three patients. On fundoscopy, normal optic discs, discrete arteriolar attenuation and single pigmentary deposits in the periphery were seen in RP5436 at 18 yo and in RP160 at 19 yo (Fig. 3). Upon visual field examinations, case RP6795 had restricted peripheral visual fields with relative paracentral scotoma (Fig. 3). Her younger female relative, RP5436, had less affected peripheral vision with arcuate relative scotomas in the mid-periphery. RP160 at 19 yo presented a large paracentral scotoma on both eyes (Fig. 3). OCT performed in RP5436 and RP160 demonstrated a general thinning of the macula with some foveal sparing (Supplementary Figure S5). The full-field standard dark-adapted ERGs are presented in Supplementary Figure S6. The amplitudes of rod, mixed rod-cone, cone and 30 Hz flicker responses were all subnormal to non-recordable in all cases at young age, meaning that the photoreceptor functions were seriously affected already in their teens. The young man, RP160, examined at age 19 and re-exam-
ined at age 30, presented several indicators of disease progression during this period. On fundoscopy the optic discs had gained a waxy pallor, alongside severe arteriolar attenuation, and an indication of a bull-eye lesion in the macula (Fig. 3). The retina was generally atrophic with the typical bone spicule pigmentation. His VF had severely deteriorated with some preserved central and peripheral islets. There was a notable progression in the visual field loss over time, going from arcuate and ring-shaped scotomas to only mid-central preservation (Fig. 3). ERG showed a decline of response amplitudes over time for both rods and cones, and the rod, mixed rod/cone responses were extinguished at age 30 (Supplementary Figure S6).

Discussion

Taken into account a relative homogeneity of the population in northern Sweden and presence of founder and family specific mutations in several retinal genes, we were looking for shared genetic causes in genetically unresolved cases of arRP in northern Sweden. In this study we investigated RP cohort including 65 arRP patients with unknown genetic cause and identified mutations in the EYS gene in 14 cases including 4 family members. Thus, the EYS mutations were present in 16% of arRP cases.

Two of six EYS mutations detected in this study were reported previously, c.1155 T>A in exon 7[18,28] and c.8648_8655del in exon 43[12,19]. Both mutations present on the same allele had been found earlier in three Finnish patients with retinal dystrophy[29]. The most common EYS variant in our study, c.8648_8655del was present in 13 cases. We were not able to connect the families of all 13 carriers but considering that 6 patients originate from the same region of Tornevalen (Pajala and Karesuando) adjacent to the Finnish boarder, it is likely that they have a common ancestor. Four of the 13 patients carried c.8648_8655del and c.1155>T>A variants in cis indicating that they share the same ancestor as the Finnish cases[28]. The Finnish origin of the cis allele might explain why we were not able to relate the Swedish families using the Swedish church records.

In two patients, RP18 and RP74 we found only one likely pathogenic variant c.8648_8655del. As we only investigated the intronic sequences adjacent to the EYS exons, a deep intronic variant as a second causal variant cannot be ruled out. The same could be true for RP65 where we found only one heterozygous missense variant, c.6284C>T reported once in a compound heterozygous arRP patient with second EYS variant c.2234A>G[29]. Both missense variants are classified as variants with uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and no functional studies have been done on either of the variants. Therefore, the pathogenicity of c.6284C>T is questionable.

A large, likely pathogenic, duplication covering an approximately 13 kb region between chr6:63,721,660 in exon 43 (c.8381) and chr6:63,734,700 (c.8072–8019) in intron 41 was identified in Family 501. However, due to the lack of additional MLPA probes we could not reveal the breakpoints of the aberration covering exon 42, as Pieras et al. could not do for the duplication of exons 3 and 4 in the EYS gene[31]. In our cohort we detected genomic rearrangements in only one family, compare to 4% EYS CNV in French cohort[31].

Since the pathogenic mechanisms in EYS-associated IRD are still poorly understood, the interpretation of the pathogenicity of many EYS variants is a challenge. The implementation of numerous computational tools to predict functionality of potentially disease-causing variants underscores the need for functional assays especially for the variants outside coding regions. According to Messchaert et al. (2018) the large size of EYS cDNA, the absence in the genome of mice and rats and the retina specific expression represent the factors limiting an experimental assessment of the pathogenicity of EYS variants[19]. In this study we assessed functionality of two intronic variants both predicted to be pathogenic due to the changes in exon–intron boundaries. By implementation of in vitro minigene assays we easily confirmed exon skipping caused by both EYS variants, c.2992_2992+6delInsTG and c.3877+1G>A. It is worth to mention that splicing outcome of in vitro minigene assays depends on the content of DNA sequences of the gene of interest and the cells chosen for the assay. We found that an inclusion of 10 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, but not in ARPE-19 cells. Computational tools revealed two alternative sites in intron 25, 10 and 14 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, indicating that they represent the factors limiting an experimental assessment of the pathogenicity of many EYS variants[19]. In this study we assessed functionality of two intronic variants both predicted to be pathogenic due to the changes in exon–intron boundaries. By implementation of in vitro minigene assays we easily confirmed exon skipping caused by both EYS variants, c.2992_2992+6delInsTG and c.3877+1G>A. It is worth to mention that splicing outcome of in vitro minigene assays depends on the content of DNA sequences of the gene of interest and the cells chosen for the assay. We found that an inclusion of 10 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, but not in ARPE-19 cells. Computational tools revealed two alternative sites in intron 25, 10 and 14 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, indicating that they represent the factors limiting an experimental assessment of the pathogenicity of many EYS variants[19]. In this study we assessed functionality of two intronic variants both predicted to be pathogenic due to the changes in exon–intron boundaries. By implementation of in vitro minigene assays we easily confirmed exon skipping caused by both EYS variants, c.2992_2992+6delInsTG and c.3877+1G>A. It is worth to mention that splicing outcome of in vitro minigene assays depends on the content of DNA sequences of the gene of interest and the cells chosen for the assay. We found that an inclusion of 10 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, but not in ARPE-19 cells. Computational tools revealed two alternative sites in intron 25, 10 and 14 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, indicating that they represent the factors limiting an experimental assessment of the pathogenicity of many EYS variants[19]. In this study we assessed functionality of two intronic variants both predicted to be pathogenic due to the changes in exon–intron boundaries. By implementation of in vitro minigene assays we easily confirmed exon skipping caused by both EYS variants, c.2992_2992+6delInsTG and c.3877+1G>A. It is worth to mention that splicing outcome of in vitro minigene assays depends on the content of DNA sequences of the gene of interest and the cells chosen for the assay. We found that an inclusion of 10 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, but not in ARPE-19 cells. Computational tools revealed two alternative sites in intron 25, 10 and 14 bp of consecutive intron 25 occurred in HEK293T cells transfected with mutant minigene EYS c.3877+1G>A, indicating that they represent the factors limiting an experimental assessment of the pathogenicity of many EYS variants[19].

Mutations in the EYS gene cause a variety of phenotypes such as RP and cone-rod dystrophy characterised by inter- and intrafamilial phenotypic diversities[10,13,32,35]. We provide clinical evaluation of only three patients from one family available for this study.

The proposed molecular mechanism of RP caused by EYS mutations is loss of protein function. The role of EYS is not yet understood but presence of epidermal growth factor-like and laminin domains might be important in cell adhesion, migration and intracellular signalling[34,35]. Also, it is known that an ortholog of the Drosophila spacemaker (spam) protein plays a critical role in maintenance of the photoreceptor morphology[36]. Currently 343 EYS mutations are reported in The Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/) with almost 44% predicted to result in protein truncation[19]. Nonsense or protein truncating variants are usually easy to classify as pathogenic according to ACMG recommendations[19] however missense and intronic variants require additional factors to be classified as likely pathogenic or pathogenic. According to the last EYS update[19] missense and splice site EYS variants represent 48.2% of all mutations, but only 8.6% can be classified as likely pathogenic while the rest are variants of uncertain significance. Lack of functional studies prevent classification of the variants as pathogenic and, thus might dismiss these variants in future genetic testing and counselling.

Many defective transcripts are degraded by nonsense-mediated mRNA decay (NMD)[37] that could also partially explain the phenotypic variation[38,39]. Recent studies on three EYS transcripts with pathogenic mutations
Figure 2. Exon skipping because of EYS c.3877+1G>A variant. (a) A schematic illustration of the pSPL3-EYS c.3877+1G>A minigene. Exon 25 of EYS gene (blue) and flanking introns (purple) were cloned into the NotI and EcoRI sites of pSPL3 vector (black) with a wildtype (wt) or mutant (mt) c.3877+1G>A between two pSPL3 exons (yellow); splice donor vector (SDv) and splice acceptor vector (SAv). Positions of SDv and SAv primers for splice site analysis are indicated. Red blocks show two alternative splice sites in exon 25 and one alternative splice site in pSPL3. In the patient's DNA used for minigene construction, a common deletion at position c.3877+18_3877+22del on the same allele as c.3877+1G>A was present. Solid and dashed lines show different outcomes of splicing. HEK293T cells and ARPE-19 cells were transfected with wt or mt EYS hybrid minigene or an empty pSPL3 vector. After RNA extraction and cDNA synthesis, splicing products were amplified by PCR using SD6 and SAv vector specific primers and visualized by agarose gel electrophoresis. Resolution of splicing PCR products derived from HEK293T are shown in (b) and from ARPE-19 in (c). Sanger sequencing confirmed that in the control pSPL3, only SDv-SAv splicing occurred, leading to a 260 bp product. Expected wt splicing of the EYS minigene was a 453 bp product. Additional splicing took place in the wt minigene transinted into HEK293T cells where incorporation of 14 bp of the 3' end of the EYS amplicon occurred, starting at c.3877+253 (red block) and continuing 97 bp into the pSPL3 vector before splicing to SAv. This aberrant splicing resulted in a 572 bp product. The same incorporation occurred in the mt minigene in HEK293T, with an additional 10 bp of consequent intron 25 sequence in the 5' end, leading to a 582 bp product. In HEK293T, mt minigene also produced an mRNA with expected splicing at the SDv-exon 25 junction, but with the incorporation of 10 bp consecutive sequence of intron 25, before joining SAv. This was not seen in ARPE-cells. In both HEK293T and ARPE-19 cells, the mt hybrid minigene resulted in exon skipping (d). Full-length gels are presented in Supplementary Figure S7.

c.1211dupA, c.4957dupA and c.8805C>A revealed barely detected, low and almost normal level of expression of the mutant allele which suggested that almost complete NMD, partial NMD and escape from NMD took place46. Interestingly, transcripts carrying the c.8805C>A mutation, that result in a premature termination codon in the last exon 43, escaped degradation by NMD and demonstrated normal expression levels46. The most common mutation in northern Sweden, c.8648_8655del and a large duplication located in exon 42 set grounds for study of a genotype–phenotype correlation.

A debatable pitfall of our study is the cascade-targeted mutation analysis of the EYS gene. Not all arRP patients in our cohort were subjected to the analysis of the entire EYS gene making it possible that some mutations escaped detection. However, our aim was to find common EYS variants in the homogenous population of northern Sweden and the 8 bp deletion found in 13 of arRP cases proved the case. The additional screening of the entire coding regions of the EYS gene in 24 unresolved arRP resulted in only one finding of a variant of uncertain significance (c.6284C>T). This leaves us with 28 unresolved arRP cases that have only been screened for the variants found in this study. The probability of finding yet another common EYS variant among these patients seems to be low.

In conclusion, our study revealed one of the most common genetic cause of autosomal recessive retinitis pigmentosa in northern Sweden. EYS mutations accounted for 16% of arRP cases with the most frequent pathogenic variant c.8648_8655del. The same mutation in cis with c.1155T>A indicated presence of Finnish founder allele in Swedish patients. We also demonstrated that in vitro minigene assay is important applicable tool for the functional analysis of intronic variants. If the pathogenic mechanisms for these variants can be determined, it will be of a great value for variant classification, molecular testing, genetic counselling, and future treatment of patients with EYS-associated RP.

Methods

Patients. In this study we used DNA from 81 patients with clinical diagnosis of retinitis pigmentosa (RP). Supposedly, 9 patients had autosomal dominant RP (adRP), 65 had autosomal recessive RP (arRP) and 7 patients had either adRP or arRP. Among arRP patients, 7 belonged to three families (Families 012, 335 and 501, Supplementary Figure S1) and the rest were simplex. Peripheral blood samples were collected in EDTA tubes and DNA was extracted as described elsewhere. The assignment of inheritance pattern was based on a family history and was performed via Asper Bio (Tartu, Estonia) (https://www.asperbio.com/asper-ophthalmics). DNA was analysed in 2006–2007 using the arrayed primer extension assay (APEX) was performed via Asper Bio (Tartu, Estonia) (https://www.asperbio.com/asper-ophthalmics). DNA was analysed in 2006–2007 using a panel for arRP-associated 501 known variants in 16 genes (CERK, Gene ID-ENSG000001188452, OMIM 608,381; CNGA1 Gene ID-ENSG00000198515, OMIM 123,825; CNGB1-ENSG00000070729, OMIM 600,724; MERTK Gene ID-ENSG00000153208, OMIM 604,705; PDE6A–Gene ID ENSG00000132915, OMIM 180,071; PDE6B–Gene ID ENSG00000132526, OMIM 180,072; PNR–Gene ID ENSG00000278570, OMIM 604,485; RDH12–Gene ID ENSG00000139988, OMIM 608,830; RGR–Gene ID ENSG00000146604, OMIM 600,342; RLBP1–Gene ID ENSG00000140522, OMIM 180,090; SAG–Gene ID ENSG00000130561, OMIM 181,031; TULP1–Gene ID ENSG00000012041, OMIM 602,280; CRB1–Gene ID ENSG00000134376, OMIM 604,210; RPE65–Gene ID ENSG00000116745, OMIM 180,069; USH2A–Gene ID ENSG00000042781, OMIM 608,400; and USH3A/CLRN1–Gene ID ENSG00000163646, OMIM 606,397).
Next generation sequencing (NGS) of 56 arRP-associated genes was performed at Asper Biogene. Samples were analysed using the BW A Enrichment app in BaseSpace (Illumina). Alignment was performed with BW A and variants were called with GATK41. Mean coverage was 87 reads for the whole gene panel and mean coverage of the EYS gene was 99 reads. Variants that had an alternative variant frequency less than 20% and/or had a call quality score lower than 20 were automatically filtered out. Confirmation of NGS findings and subsequent screening of the EYS gene was done with Sanger sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Primer sequences for the screening of the EYS gene are available upon request. The products of sequencing reactions were analysed on ABI 3500xL Dx Genetic Analyser (Applied Biosystems). Sequences were aligned and evaluated using the Sequencher software version 4.9 (Gene Codes Corporation, Ann Arbor, MI, USA). All changes were assigned according to the GenBank Reference Sequence Version FJ416331; GI: 212,675,237; Transcript Reference Sequence: NM_001142800.1 and described according to the HGVS recommendations42.

For detection of copy number changes in exonic sequences of the EYS gene we used Multiplex Dependent Probe Amplification (MLPA) with SALSA MLPA Probe mix P328-A1-0811 or P328-A2-0217 lacking probes for exon 9 or exons 2, 7, 9 and 27, respectively (MRC Holland, Amsterdam, Netherlands). Additionally, three MLPA

Table 3. Clinical characterization of patients with EYS associated RP in family 501. M male, F female, NB night blindness, VA visual acuity, OD right eye, OS left eye. + sign = present; – sign = not present.

| Case/sex/age | Onset age of NB | VA LogMAR OD/OS | Refractive errors OD/OS | Photophobia |
|--------------|----------------|-----------------|------------------------|------------|
| RP6795/F/15  | 12             | 0.00/−0.20      | +0.25/ +0.25           | −          |
| RP5436/F/18  | 18             | 0.00/0.10       | +0.4/ +0.5             | +          |
| RP160/M/19   | 15             | 0.20/0.10       | −2.0/ −0.75            | +          |
| RP160/M/30   | 15             | 0.50/0.30       | −1.5/ −1.0             | +          |

Figure 3. Fundus photographs (a) and visual fields (b) in affected family members RP6795, female, examined at 15 yo; RP5436, female, examined at 18 yo; RP160, male, examined at 19 and 30 yo. Paracentral scotomas are seen in RP6795, and RP5436. Absolute paracentral scotomas were seen in RP160 at 19 yo that advanced to minor central/peripheral islets when re-examined at 30 yo. Absolute scotomas are shown as stripes and relative scotomas are shown as checkered.
Human Retinal Pigmented Epithelium cells, ARPE-19 (ATCC CRL-2302, Manassas, VA, USA) were transfected midi-preparation using NucleoBond Xtra Midi kit (Macherey–Nagel, Düren, Germany). wildtype minigene construct in the pSPL3 vector, the clones were propagated, and plasmid DNA was purified by adding the pGEM-T ligation reaction to 50 μl of XL10-Gold ultracompetent cells. Ratios for pSPL3 versus inserts were calculated using an online tool at www.promega.com/a/apps/biomath/?calc=ratio. Sequence confirmation was done by Sanger sequencing with pSPL3 specific primers: forward SD6-5’-TCTGAGTCACTGGACACCCGCA-3’ and reverse SA2-5’-ATCTCAGTGGATTTTGTGACGCG-3’. For minigene construction, pSPL3 was digested with EcoRI and NotI and the wildtype and mutant inserts excised from pGEM-T Easy vector as described previously43. Genomic DNA from RP103 and RP15 patients was used for PCR amplification for fragments with EYS c.3877+1G>A and c.2992_2992+6delinsTG, respectively. PCR was performed in 25 μl volume with 0.2 μM forward primer with EcoRI- and reverse primer with NotI at 5’-endsites (Supplementary Table S1) and 1.25U of Taq-DNA polymerase with 5’-3’ exonuclease activity (Ampliqon A/S, Odense, Denmark). Ligation of the amplicons was performed according to manufacturer’s instructions by adding 50 ng of pGEM-T Easy vector (Promega, Fitchburg, WI, USA), 3 μl of PCR product, 3U of T4 ligase and 1X Rapid Ligation buffer to a final reaction volume of 10 μl. For propagation of the pGEM-T Easy vector, XL10-Gold ultracompetent cells (Stratagene, La Jolla, CA, USA) were transformed by transformation into XL10-Gold ultracompetent cells. Human Embryonic Kidney cells, HEK293T Lenti-X (Clontech Laboratories, Mountain View, CA, USA) and Human Retinal Pigmented Epithelium cells, ARPE-19 (ATCC CRL-2302, Manassas, VA, USA) were transfected with wt and mt pSPL3 minigenes, (EYS c.3877+1G>A and EYS c.2992_2992+6delinsTG). 2 × 105 HEK293T or ARPE-19 cells were seeded in 24-well plates. HEK293T cells were cultures in DMEM medium (Gibco Laboratories, Gaithersburg, MD, USA) containing 1X Glutamax (Gibco) and ARPE-19 cells were grown in DMEM: F12 medium (Gibco). Both growth medium additionally contained 10% fetal bovine serum (Gibco) and 1X PenStrep (Gibco). Cells were transfected after 24 h using the Lipofectamine 3000 system (Thermo Fisher Scientific). All transfections were performed twice with HEK293T and once with ARPE-19 cells. For each well, 1 μl Lipofectamine 3000 and 0.8 μg pSPL3 vector DNA was used. Total RNA was extracted 46–48 h after transfection with NucleoSpin RNA Plus (Macherey–Nagel) and reverse transcribed into cDNA in 20 μl reactions containing 100U Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA), 200 ng random hexamers (Thermo Fischer), 0.5 mM dNTP (Roche Diagnostics, Mannheim, Germany), 5 mM DTT (Invitrogen), 1 x First Strand Buffer (Invitrogen) and 128–1000 ng RNA. The cDNA reactions were incubated at 25 °C for 5 min, 50 °C for 60 min and 70 °C for 15 min. Thereafter, PCR was performed on 5 μl cDNA (estimated 32–100 ng) using pSPL3 specific primers SD6 and SA2 (Supplementary Table S1), 0.75U AmpliTaq Gold DNA Polymerase, (Applied Biosystems), 1 x PCR Buffer II (Applied Biosystems), 1.5 mM MgCl2, (Applied Biosystems) 0.2 mM dNTP (Roche Diagnostics) with a temperature profile of 95 °C for 12 min followed by 35 cycles of 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s and a final extension at 72 °C. The PCR products were separated on 1% agarose gels and visualized under UV-light using ethidium bromide.

**Clinical evaluation.** A full ophthalmic examination was performed at Eye Clinic of northern Sweden, and the clinical diagnosis was based on visual acuity, electroretinography (ERG) findings, fundus photography and Optical Coherence Tomography (OCT) visual fields.

**Psychophysical methods and clinical examination.** Visual acuity (VA) was measured using a LogMAR (Logarithm of the Minimum Angle of Resolution) chart. Slit-lamp examination, biomicroscopy and fundus examinations were performed, and fundus images were taken. Visual fields were measured with a Goldmann perimeter. Macular morphology and thickness were measured with optical coherence tomography (OCT), using a Topcon 3D OCT 2000 (Topcon Medical Systems, Oakland, NJ, USA). A pseudo-colour two-dimensional map of retinal thickness was used to confirm the retinal morphology.

**Electrophysiological methods.** Full-field electroretinograms (ERG) were recorded using Burian-Allens bipolar electrodes on an Espion Profile Ganzfeld ERG machine (Diagnosys LLC, Lowell, MA, USA) following the recommendations from the international society of Clinical Electrophysiological Vision44,45.
Computational resources. For the interpretation of genomic variants, prediction of splicing effect and estimation of alternative splice junctions Alamut Visual v2.9 (Interactive Biosoftware, Rouen, France) was used. To obtain splicing scores, the following software programs were applied: SpliceSiteFinder-like, MaxEntScan, NNSPLICE, Genesplicer, and Human Splice Finder. Frequencies of the variants present in controls were extracted from the Genome Aggregation Database (gnomAD) Version 2.1, which includes data of 125,748 exome sequences and 15,708 whole-genome sequences (https://exac.broadinstitute.org). We also used The Human Genome Variant Search Engine, VarSome. In this search engine information from more than 30 public databases is available with various annotations and predictions. Pathogenicity classification of sequence variants based on ACMG guidelines was automatically done in VarSome and controlled manually. According to the guidelines, variants can be classified as pathogenic, likely pathogenic, benign, likely benign, or uncertain significance using criteria for pathogenicity a) pathogenic, very strong (PVS) b) pathogenic, strong (PS); c) pathogenic, moderate (PM); and d) pathogenic, supporting (PP).

Ethics approval. This study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten) (Dnr:2019–01744 dated 2nd April 2019).

Consent to participate. Informed written consent was obtained from all participants of this study. For patient RP7695 written consent was obtained from her parents.

Consent for publication. We confirm that we have obtained written permission to use data from all individuals included in this article.

Data availability The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files. The datasets generated, used, and analysed during this study are available from the corresponding author on reasonable request.

Received: 16 November 2020; Accepted: 25 March 2021
Published online: 08 April 2021

References
1. Fähim, A. T., Daiger, S. P. & Weleber, R. G. in GeneReviews(R) (eds M. P. Adam et al.) (1993).
2. Haim, M. Epidemiology of retinitis pigmentosa in Denmark. Acta Ophthalmol. Scand Suppl., 1–34, https://doi.org/10.1046/j.1395-3907.2002.00001.x (2002).
3. Boughnann, J. A., Connally, P. M. & Nance, W. E. Population genetic studies of retinitis pigmentosa. Am. J. Hum. Genet. 32, 223–235 (1980).
4. Rosenberg, T. Epidemiology of hereditary ocular disorders. Dev. Ophthalmol. 37, 16–33. https://doi.org/10.1159/000072036 (2003).
5. Golovleva, I., Kohn, L., Burstedt, M., Daiger, S. & Sandgren, O. Mutation spectra in autosomal dominant and recessive retinitis pigmentosa in northern Sweden. Adv. Exp. Med. Biol. 664, 255–262. https://doi.org/10.1007/978-1-4419-1399-9_29 (2010).
6. Xu, L., Hu, L., Ma, K., Li, J. & Jonas, J. B. Prevalence of retinitis pigmentosa in urban and rural adult Chinese: The Beijing Eye Study. J. Ophthalmol. 16, 865–866. https://doi.org/10.1177/12067210601600614 (2006).
7. Sen, P. et al. Prevalence of retinitis pigmentosa in South Indian population aged above 40 years. Ophthalm. Epidemiol. 15, 279–281. https://doi.org/10.1080/09286580802105814 (2008).
8. Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. Lancet 368, 1795–1809. https://doi.org/10.1016/S0140-6736(06)69740-7 (2006).
9. Kajiwara, K., Berson, E. L. & Dryja, T. P. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264, 1604–1608. https://doi.org/10.1126/science.8202715 (1994).
10. Abd El-Aziz, M. M. et al. EYS, encoding an ortholog of Drosophila eyes shut/spacemaker that is mutated in patients with autosomal recessive retinitis pigmentosa. Nat Genet. 40, 1285–1287, https://doi.org/10.1038/ng.241 (2008).
11. Collin, R. W. et al. Identification of a 2 Mb human ortholog of Drosophila eyes shut/spacemaker that is mutated in patients with retinitis pigmentosa. Am. J. Hum. Genet. 83, 594–603. https://doi.org/10.1016/j.ajhg.2008.10.014 (2008).
12. Littin, K. W. et al. Mutations in the EYS gene account for approximately 5% of autosomal recessive retinitis pigmentosa and cause a fairly homogeneous phenotype. Ophthalmology 117, 2026–2033, 2033 e2021–2027, https://doi.org/10.1016/j.ophtha.2016.01.040 (2010).
13. Audo, I. et al. EYS is a major gene for rod-cone dystrophies in France. Hum. Mutat. 31, E1406-E1435. https://doi.org/10.1002/humu.21249 (2010).
14. Bandah-Rosenfeld, D. et al. Novel null mutations in the EYS gene are a frequent cause of autosomal recessive retinitis pigmentosa in the Israeli population. Invest. Ophthalmol. Vis. Sci. 51, 4387–4394. https://doi.org/10.1167/iovs.09-4732 (2010).
15. Hosono, K. et al. Two novel mutations in the EYS gene are possible major causes of autosomal recessive retinitis pigmentosa in the Japanese population. PLoS ONE 7, e31036. https://doi.org/10.1371/journal.pone.0031036 (2012).
16. Gu, S., Tian, Y., Chen, X. & Zhao, C. Targeted next-generation sequencing extends the phenotypic and mutational spectrums for EYS mutations. Mol. Vis. 22, 646–657 (2016).
17. Iwanami, M., Oshikawa, M., Nishida, T., Nakadomari, S. & Kato, S. High prevalence of mutations in the EYS gene in Japanese patients with autosomal recessive retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 53, 1033–1040. https://doi.org/10.1167/iovs.11-9048 (2012).
18. Mcguigan, D. B. et al. EYS mutations causing autosomal recessive retinitis pigmentosa: changes of retinal structure and function with disease progression. Genes (Basel) 8, 10. https://doi.org/10.3390/genes8070178 (2017).
19. Messchaert, M., Haer-Wigman, L., Khan, M. I., Cremers, F. P. M. & Collin, R. W. J. EYS mutation update: In silico assessment of 271 reported and 26 novel variants in patients with retinitis pigmentosa. Hum. Mutat. 39, 177–186. https://doi.org/10.1002/humu.23371 (2018).
20. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424. https://doi.org/10.1038/gim.2015.30 (2015).
The authors declare no competing interests.

Competing interests

Margaretas Arbetsnämnd för Synskadade (Valdemarsvik, Sweden) (MB, IG).

Open access funding provided by Umeå University. Financial support was obtained through regional agreement between Umeå University and Västerbotten County Council on cooperation in the field of Medicine, Odontology and Health (ALF) (MB, IG), from Ogonfonden (Gothenburg, Sweden) (MB, IG) and from Kronprinsessan Margaretas Arbetsnämnd för Synskadade (Valdemarsvik, Sweden) (MB, IG).

Acknowledgements

The authors thank all patients for participation in this study and acknowledge collaboration with Asper Biogene, Tartu, Estonia.

Author contributions

I.M.W., M.H. and I.G. designed the study; F.J. performed mutation screening by sequencing and MLPA.; I.M.W., L.O. and F.J. make constructs; I.M.W. performed cell culturing and splicing assays; M.B. examined the patients, prepared the Fig. 3, the Table 3 and Supplementary Information. I.M.W. and I.G. prepared Figs. 1 and 2. I.M.W. and F.J. prepared Tables 1 and 2. Everyone contributed in the Supplementary Information. I.M.W. wrote original draft and everyone edited it. M.B. and I.G. received funding for the project. All authors reviewed the manuscript.

Funding

Open access funding provided by Umeå University. Financial support was obtained through regional agreement between Umeå University and Västerbotten County Council on cooperation in the field of Medicine, Odontology and Health (ALF) (MB, IG), from Ogonfonden (Gothenburg, Sweden) (MB, IG) and from Kronprinsessan Margaretas Arbetsnämnd för Synskadade (Valdemarsvik, Sweden) (MB, IG).

Competing interests

The authors declare no competing interests.
Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-87224-9.

Correspondence and requests for materials should be addressed to I.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021